Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated
Abstract Glioblastoma is the deadliest primary brain tumor, largely due to inevitable recurrence of the disease after treatment. While most recurrences are local, patients rarely present with a new discontiguous focus of glioblastoma. Little is currently known about the genetic profile of discontigu...
Saved in:
Main Authors: | Malcolm F. McDonald, Sricharan Gopakumar, Tareq A. Juratli, Ilker Y. Eyüpoglu, Ganesh Rao, Jacob J. Mandel, Ali Jalali |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Acta Neuropathologica Communications |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40478-024-01900-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01) -
IDH-mutant gliomas in children and adolescents - from biology to clinical trials
by: Louise Evans, et al.
Published: (2025-01-01) -
Increased RTN3 phenocopies nonalcoholic fatty liver disease by inhibiting the AMPK–IDH2 pathway
by: Hao Huang, et al.
Published: (2023-04-01) -
Dermoscopy of Periungual Papules in Multicentric Reticulohistiocytosis
by: José María Llamas-Molina, et al.
Published: (2025-01-01) -
Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3
by: Liv Cathrine Heggebø, et al.
Published: (2025-01-01)